



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 39/00, 39/38, 39/385, 39/12, 39/05, 39/07, 39/002, 39/012, C12N 1/12, 1/20	A1	(11) International Publication Number: WO 99/43348 (43) International Publication Date: 2 September 1999 (02.09.99)
(21) International Application Number: PCT/US99/03498 (22) International Filing Date: 18 February 1999 (18.02.99) (30) Priority Data: 09/032,141 27 February 1998 (27.02.98) US (71) Applicant: MUNOVA CORPORATION [US/US]; Suite 150, 3507 Frontage Road, Tampa, FL 33607 (US). (72) Inventors: BROWN, Jenaay, M.; 9336 Hampshire Park Drive, Tampa, FL 33647 (US). MCDUGALD, Larry, D.; 1790 Saxon Road, Watkinsville, GA 30677 (US). (74) Agents: SEELEY, David, O. et al.; Workman, Nydegger & Seeley, 1000 Eagle Gate Tower, 60 East South Temple, Salt Lake City, UT 84111 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: IMMUNOSTIMULATION METHODS FOR PROVIDING DISEASE PROTECTION IN POULTRY		
(57) Abstract <p>Methods for providing improved immunization against coccidiosis and other bacterial, viral, or parasitic diseases in poultry. One method includes administering a solution of <i>Propionibacterium acnes</i> suspended in normal saline to a chick at age day one, following hatching. An anticoccidial vaccine and/or other vaccine is then administered to the chick such as by oral administration. Alternatively, the method includes the steps of aseptically injecting <i>Propionibacterium acnes in ovo</i> at about day 18 in development, followed by post-hatching vaccination with an anticoccidial vaccine and/or other vaccine. Alternatively, either method can be utilized without the subsequent vaccination step for stimulating non-specific cell-mediated immune responses in poultry.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

IMMUNOSTIMULATION METHODS FOR PROVIDING DISEASE PROTECTION IN POULTRY

BACKGROUND OF THE INVENTION

1. The Field of the Invention

The present invention is directed generally to methods and apparatus for preventing diseases in poultry. More specifically the present invention is related to methods and apparatus for immunizing poultry against diseases caused by bacteria, viruses, and parasites.

2. The Relevant Technology

Commercial poultry husbandry and breeding practices have resulted in immune system deficiencies in chickens making disease more prevalent and devastating to the birds.

Coccidiosis is a disease which costs the poultry industry hundreds of millions of dollars annually. This disease is primarily caused by parasites from the genus *Eimeria*. These parasites have short, direct life cycles and high reproductive potentials which intensifies the potential for outbreaks of disease, especially where 15-30,000 chickens are housed in total confinement. McDougald, L. R., Reid, W. M., *Coccidiosis*, Diseases of Poultry, (B. W. Calnek et al. eds., 10th ed. 1997).

Eimeria parasites multiply in the intestinal tract where they cause tissue damage. This further results in the interruption of feeding and digestive processes or nutrient absorption; dehydration; blood loss; and increased susceptibility to other disease agents. Further, immunosuppressive diseases may act in concert with coccidiosis to produce a more severe disease. *Id.*

Coccidia are almost universally found wherever chickens are raised, and especially in broiler farms where the chickens are kept for only about 6-8 weeks prior to market. The ubiquitous nature of coccidia in poultry precludes the possibility of elimination or prevention of coccidia by quarantine, disinfection, and sanitation. *Id.*

Coccidial infections depend largely on the number of parasite oocysts ingested and on the immune status of the bird. Characteristics useful in identification of the species of parasite include location of the lesions in the intestine; appearance of the gross lesion; oocyst size, shape and color; location of parasites in tissues; etc. *Id.*

Prevention of this disease has been attempted by supplying young poultry with continuous medication of anticoccidial drugs. Vaccines against coccidiosis have met

with limited success and have been used mostly in breeders and in turkeys. Conventionally, vaccination of broilers was rare due to the risk associated with the birds contracting a light infection from the vaccine, which could affect weight gain, feed conversion, and skin pigmentation. *Id.*

SUMMARY OF THE INVENTION

The present invention relates to new and useful methods for inoculating poultry, especially broiler chickens, against coccidiosis. One preferred method administers *P. acnes* in saline to chicks intraperitoneally at about one day of age. Another preferred method inoculates chicks *in ovo* at about day 18 with a preparation of *Propionibacterium acnes* in saline.

In an alternate embodiment, the chicks are further vaccinated with an anticoccidial vaccine. Alternatively, vaccines for bacterial, viral, or other parasitic diseases are utilized in place of or in conjunction with the anticoccidial vaccine.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Immunization is the process by which an immune response is induced for protection against certain diseases. An immune response is either "humoral" or "cell-mediated." A humoral response is initiated when a foreign protein, or, "antigen," activates the production of antibodies designed to specifically attach to the foreign protein that induced them. Cell-mediated immune responses involve the production of specialized cells that react with antigens on the surface of host cells, either killing the host cell or inducing other cells (macrophages) to destroy the antigen. Unlike the humoral antibody response, cell-mediated responses are not specific to the antigen that induced them.

Commercial poultry husbandry has resulted in immune system deficiencies in poultry, making them more susceptible to disease. Various immunization techniques have been developed in an attempt to counteract the effects of the reduced immunity.

One of the main types of immunization involves the use of vaccines, which are utilized for specific (humoral) stimulation of the immune system. In a vaccination, killed or weakened pathogenic microorganisms are introduced into the body to sensitize the immune system to those pathogens. If disease-causing organisms of the same type later enter the body, the immune system should quickly destroy them.

Certain vaccines have been developed for administration *in ovo*. It is believed vaccination prior to hatching of the chick reduces the amount of post-hatch chick handling and eliminates the stress of individually injecting the newly hatched chicks, which leads to improved chick performance. Further, it is believed that when the embryo

is vaccinated *in ovo*, disease resistance builds during the last days of incubation and provides the hatched chicks with a head start on resisting disease. A system known as Inovoject® manufactured by Embrex, Inc., injects biologically active compounds *in ovo*, directly into the egg, just 3 days before the chick is hatched. When the chick hatches,
5 it is already vaccinated and ready for transport to a growout farm. Embrex, Inc., *Inovoject® Egg Injection System Product Literature* (1992).

Further, *in ovo* inoculation on day 18 of incubation with a material (an immunostimulant inducing lymphokines) which non-specifically stimulates the immune system was found to decrease early chick mortality by 30 to 50% below the controls in
10 numerous trials involving eggs from commercial broiler breeder flocks. It was suggested that this protocol would have practical application in stimulating the resistance of broiler chicks to early mortality associated with *E-coli* organisms. Andrea M. Miles, *et al.*, *Abstract: Efficacy of an Immunostimulant Administered in Ovo Against Early Chick Mortality* (1993).

15 A vaccine against Infectious Bursal Disease has also been developed for delivery *in ovo*. However, it is currently believed that other vaccines are risky and unsafe when delivered into the embryo, causing the chicks to be born sick or stillborn. Rod Smith, *Embrex Receives Approval of First in Ovo IBD Vaccine*, *Feedstuffs* at 6 (March 17, 1997).

20 Coccidiosis is a serious parasitic disease in poultry. Vaccines against this disease have met with limited success. In broiler chickens, for example, vaccination may result in the appearance of a light infection which can detrimentally effect the commercial characteristics of the birds.

The present invention is directed to an improved method for inoculating chicks
25 at an early developmental stage against coccidiosis-type diseases. Specifically, the present invention is directed to the use of *Propionibacterium acnes* for stimulating non-specific cell mediated immune responses in poultry at an age as early as day one, or even *in ovo*, to combat coccidiosis and other poultry diseases.

Poultry as the term is used herein refers to one or a plurality of game or
30 domesticated birds for use as food, such as chickens, turkeys, quail, pheasants, ratites (flightless birds), etc. The methods of the present invention are also useful for preventing disease in exotic and domesticated pet birds; thus the general term poultry is meant to encompass those birds as well.

Further, as the term is used herein, "chick" is meant to refer to young birds *in ovo*
35 or post-hatching, and up to about four to six weeks of age. The term *in ovo* refers to the

embryonic developmental stage of the chick prior to hatching. In addition, as the term is used herein, chick refers to any type of poultry, although it will be appreciated that broiler chickens are the preferred poultry recipients for the methods of the present invention. Thus, for the purposes of the present invention, the developmental stages and characteristics described herein are directed to broiler chickens. One of skill in the art could easily determine the appropriate corresponding developmental stage for other types of poultry.

The standard incubation time for an embryonic chick is twenty-one days. Thus, a chick is typically *in ovo* for about twenty-one days prior to hatching. After hatching, the chick is referred to as being a certain age old, i.e., the chick is one day old, or three weeks old. The day that the chick hatches is considered to be day zero for the purposes of this invention.

The components necessary to effectuate the methods of the present invention comprise the microorganism, *Propionibacterium acnes*, and a diluent in which the *Propionibacterium acnes* is suspended.

Propionibacterium acnes, hereinafter, "*P. acnes*," is an immunostimulant for providing non-specific cell-mediated immune response in poultry. *P. acnes* is available in a variety of forms including freeze-dried (lyophilized), liquid suspension, or dried powder. A dried powder form of *P. acnes* is the presently preferred embodiment for the method of the present invention.

The *P. acnes* is preferably suspended in a diluent. A preferred diluent for suspending the *P. acnes* is normal, also referred to as "physiological," saline solution. Alternatively, an amino acid diluent is utilized in accordance with the present invention.

It should be appreciated that other diluents capable of suspending the *P. acnes* for administration into chicks could be utilized in accordance with the present invention.

Alternatively, a variety of materials can be added to a diluent in accordance with the present invention depending on the requirements of the chicks. For example antibiotics (gentamicin, ceftiofur, and erythromycin), vaccines (Marek's Disease vaccine, Infectious Bursal Disease vaccine), vitamins, growth media (tryptose phosphate), meat digests, and/or food colorings may be added to a diluent in accordance with the present invention.

The *P. acnes* is preferably suspended in a normal saline diluent at about 0.5 mg to about 10 mg dried weight per milliliter of diluent. It will be appreciated that other initial concentrations of the *P. acnes* suspension are within the scope of the present invention because the actual administration to the chick is preferably adjusted and further

diluted with diluent for optimum dosages. The optimum dosage for administration of the *P. acnes* suspension depends upon the different modes of administration, which will be described in more detail hereinbelow, and also on the amount of *P. acnes* suspension, hereinafter the "effective amount," which results in stimulation of the immune system such that the effects of coccidiosis, including deaths, intestinal lesions, and weight loss, are reduced.

For example, in one preferred mode of administration, the *P. acnes* suspension is administered to the chick at a concentration of about 20 $\mu\text{g/ml}$. Those of skill in the art will appreciate that the starting concentration of the *P. acnes* suspension is simply diluted with the same diluent in which the *P. acnes* was originally suspended until a desired final dose is realized.

In a preferred method of the present invention, an effective amount of *P. acnes* suspension such as that described herein above is administered to hatched chicks. The preferred age for hatched chicks ranges from immediately post-hatching to about one week old. A more preferred age for hatched chicks ranges from about day zero to about three days old. The most preferred age for hatched chicks is about one day old.

A preferred dose in accordance with the method of the present invention is about 0.1 ml of *P. acnes* suspension at a range from about 0.5 $\mu\text{g/chick}$ to about 16 $\mu\text{g/chick}$. A more preferred dose in accordance with the method of the present invention is about 0.1 ml of *P. acnes* suspension at a range from about 1.5 $\mu\text{g/chick}$ to about 3.5 $\mu\text{g/chick}$. A most preferred dose in accordance with the method of the present invention is about 0.1 ml of *P. acnes* suspension at a dose of about 2 $\mu\text{g/chick}$.

The preferred mode of administration of the *P. acnes* suspension for hatched chicks is via intraperitoneal injection. Alternatively, the *P. acnes* suspension is administered to hatched chicks via subcutaneous injection in a method substantially similar to that described hereinabove.

In an alternate embodiment of the present invention, the method described above includes an additional vaccination step. For example, the hatched chicks are preferably vaccinated against coccidiosis via oral administration of an anticoccidial vaccine. One example of such a vaccine is Immucox® anticoccidial vaccine available from Vetech Laboratories. Alternatively, Coccivax® by Schering-Plough, or other commercial or autogenous vaccine is utilized. Alternatively, coccidial antigen may be utilized. It will also be appreciated that vaccines against other poultry diseases may be utilized in accordance with the method of the present invention. Any of the aforementioned vaccines can be provided to the chick *in ovo* or post hatch.

In one preferred embodiment of the present invention, the vaccination step is performed following administration of the *P. acnes* suspension. For example, the vaccination is administered via the food supply to the chicks at the age of about day three and beyond. Alternatively, the vaccine is incorporated into the food supply from day zero. Alternatively, the vaccine is administered simultaneously with the *P. acnes* suspension.

In an alternate embodiment of the method of the present invention, *P. acnes* is suspended in a diluent solution such as described hereinabove and administered to hatched chicks via an eye spray. The eye spray administration method does not cause the pain and stress to older chicks associated with conventional inoculation techniques. As the term is used herein, eye spray is synonymous with "in-house" spray, which is known by those of skill in the art to be used with older chicks.

The preferred time period during which eye spray is administered to chicks ranges from immediately after hatching to about four weeks or older. A more preferred time period ranges from about one day to about three weeks old.

A preferred dose for eye spray administration is *P. acnes* suspension at a range from about 2 $\mu\text{g}/\text{chick}$ to about 16 $\mu\text{g}/\text{chick}$. A more preferred dose for eye spray administration is *P. acnes* suspension at a range from about 6 $\mu\text{g}/\text{chick}$ to about 10 $\mu\text{g}/\text{chick}$. A most preferred dose for eye spray administration is *P. acnes* suspension at dose of about 8 $\mu\text{g}/\text{chick}$.

In an alternate embodiment of the eye spray administration method described above, an added step of vaccinating the chick with an anticoccidial vaccine and/or a vaccines against other diseases of poultry is performed.

In one embodiment, vaccination is performed at approximately the same time as the eye spray administration of the *P. acnes* solution. Alternatively, the vaccination is performed through oral administration following hatching of the chicks such at day zero, day one, and/or beyond.

In another alternate embodiment of the method of the present invention, *P. acnes* is administered to the chick *in ovo* during the embryonic development period. Prior to the present invention, it was believed that *in ovo* inoculation against coccidiosis would be detrimental to the chicks. The results of *in ovo* administration of *P. acnes*, however, illustrate that this is an effective method to stimulate non-specific cell-mediated immune response and prevent coccidiosis disease in chicks. See, e.g., Example 16, below.

To perform the *in ovo* method of the present invention, *P. acnes* is preferably

suspended in a diluent solution such as described hereinabove. A preferred diluent solution is physiological saline.

An effective amount of the *P. acnes* suspension is then administered to chicks *in ovo*. The preferred developmental stage for administration to chicks *in ovo* ranges from about day 14 to immediately prior to hatching at about day 21. A more preferred developmental stage ranges from about day 17 to about day 19. The most preferred developmental stage for administration *in ovo* is at about day 18.

A preferred dose for *in ovo* administration is about 0.1 ml of *P. acnes* suspension at a range from about 2 $\mu\text{g/egg}$ to about 12 $\mu\text{g/egg}$. A more preferred dose for *in ovo* administration is about 0.1 ml of *P. acnes* suspension at a range from about 6 $\mu\text{g/egg}$ to about 10 $\mu\text{g/egg}$. A most preferred dose for *in ovo* administration is about 0.1 ml of *P. acnes* suspension at dose of about 8 $\mu\text{g/egg}$.

The *P. acnes* suspension is preferably injected through the large end of the egg at about one inch into the chorioallantoic membrane. Injection *in ovo* is preferably carried out under aseptic conditions.

In an alternate embodiment of the *in ovo* administration method described above, an added step of vaccinating the chick with an anticoccidial vaccine and/or vaccines against other diseases of poultry is performed.

In one embodiment, vaccination is performed simultaneously with the *in ovo* administration of the *P. acnes* solution. Alternatively, the vaccination is performed through oral administration following hatching of the chicks such at day zero, day one, and/or beyond.

With the exception of Example 1, the examples which follow are included to illustrate the effectiveness of *P. acnes* in preventing coccidiosis. The examples are meant to be illustrative only, and are not meant to limit the embodiments of the present invention.

With respect to the results of the studies depicted in the following examples, care should be taken to avoid drawing any conclusions based on the number of deaths, intestinal lesions, or on the weight gain alone. These factors should to be taken into account as a whole in determining the effectiveness of the various study parameters.

In Example 1, immunostimulants were utilized in conjunction with an anticoccidial vaccine in an attempt to ameliorate the difficulties associated with conventional vaccination against coccidiosis.

Example 1 (Prior Art)

Three week old chickens were immunized intramuscularly with a mixture of anticoccidial vaccine and an immunostimulant of either *Propionibacterium acnes* (previously known as *Corynebacterium parvum*), or Complete Freund's adjuvant (CFA).
5 The chickens were challenged ten days after immunization with the coccidial parasite, *Eimeria tenella*. Oocyst production was determined by collecting fecal samples 5-9 days following the coccidial challenge. The results of the study indicated that chickens immunized with CFA and anticoccidial vaccine showed significantly lower oocyst production than the controls immunized with CFA alone. However, when compared with
10 the controls immunized with CFA alone, the *P. acnes* did not differ with respect to development of protective immunity. Lillehoj, H.S., Linblad, E. B., Nichols, M., *Adjuvanticity of Dimethyl Dioctadecyl Ammonium Bromide, Complete Freund's Adjuvant and Corynebacterium parvum with Respect to Host Immune Response to Coccidial Antigens*, 37 Avian Diseases 731 (1993).

15 In accordance with the investigations associated with the present invention, it is believed that vaccination at such as that described in Example 1 (three weeks or older) is unacceptable. Vaccination at this stage in development requires the difficult, painful, and impractical collection and inoculation of substantially grown chicks.

20 Additionally, the intramuscular administration associated with the method in Example 1 makes it difficult for the *P. acnes* to reach the immune system cells, macrophages, whose function it is to protect the body against infection.

For Examples 2 through 4, the following materials and methods were utilized and substantially duplicated for each example:

Materials and methods

25 Mixed sex, day-old domestic broiler chicks (*Gallus domesticus*), were obtained from a research flock (Peterson males and Arbor Acres females). The chicks were randomly assigned, using a statistical analysis system (SAS) randomization program, to different treatment groups, depending upon the investigation performed. The *P. acnes* was reconstituted and diluted with physiological saline. The *P. acnes* was kept in
30 solution by occasional agitation of the container. The groups that did not receive *P. acnes* were treated in the same manner with physiological saline (sham inoculated). After hatching, the chicks were moved to an environmentally controlled building where they were housed separately by treatment group in 4' x 10' plastic mesh floor pens, and placed on fresh litter. Incandescent lamps were used for additional brooding heat. A
35 standard broiler starter ration and water were available *ad libitum*.

On about day 12, healthy chicks were selected from each treatment group, wing banded with individual numbers, weighed and moved to 6 Petersime battery cages (27" X 27" X 12"), housing 10 birds each. The excess birds were euthanized and incinerated.

Six days later, all birds were weighed, their body weights were recorded, and they were euthanized by cervical dislocation. Necropsies were then conducted on all birds and intestinal lesions were scored according to the Johnson and Reid scoring system. All remains were incinerated.

Experimental data

Intestinal lesions, deaths, and weight gain were used for comparative analysis to determine the effectiveness of the *P. acnes* against coccidial infection. Intestinal lesions are indicative of different *Eimeria* species depending upon the location of the lesions in the intestine. Upper intestinal lesions indicate *E. acervulina* infection; middle intestinal lesions indicate *E. maxima* infection; cecal lesions indicate *E. tenella* infection.

Bodyweight gains are useful in determining coccidial infections because low weight is an indication of poor absorption of nutrients which is a primary symptom of a coccidial infection. These factors are analyzed as a whole for determination of the effectiveness of the *P. acnes* against coccidiosis.

General Linear Models (GLM) procedure for ANOVA and Duncan's Multiple Range Test was used for comparisons between treatment groups. Different superscript letters within a column in one of the following tables indicate a significant difference ($p \leq .05$).

Example 2

On day one, 100 chicks (group one) were injected intraperitoneally with *P. acnes* at a dose of 4.0 μg /chick with an injection volume of 0.1 ml, and 200 chicks (groups two and three) received sham inoculation of physiological saline. None of the chicks received anticoccidial vaccine or any other drugs or vaccines during the study.

On about day 12, 60 chicks from group one and 60 chicks from group two were challenged with *Eimeria* species as follows: 50,000 *E. tenella* and 500,000 *E. acervulina* live oocysts by oral gavage.

The results of this study are depicted in Tables 2-4, below.

TABLE 2

Group	<i>P. acnes</i>	Challenge	Upper Score	Cecal Score
1	4.0 μg	Yes	3.1 ^a	3.2 ^a
2	0.0 μg	Yes	3.2 ^a	3.0 ^{a,b}
3	0.0 μg	No	0.0 ^c	0.0 ^d

Table 3, below, depicts the number of coccidiosis-related deaths per treatment group six days following the coccidial challenge.

TABLE 3

Group	Treatment Protocol	Coccidiosis Deaths
1	4.0 μ g <i>P. acnes</i> , challenged	2
2	0.0 μ g <i>P. acnes</i> , challenged	4
3	0.0 μ g <i>P. acnes</i> , not challenged	0

Body weights were measured at six days post challenge and the weight gains were calculated. The mean weight gains are illustrated in Table 4, below.

TABLE 4

Group	<i>P. acnes</i> (μ g)	Challenge	Gains (gms.)
1	4.0	Yes	194.2 ^c
2	0.0	Yes	169.2 ^d
3	0.0	No	278.8 ^a

Discussion and Conclusions

When the results are viewed as a whole, a dose of 4.0 μ g of *P. acnes* given intraperitoneally to day-old broiler chickens enhanced their immune response and decreased the negative effects of coccidiosis.

Example 3

The procedure from Example 2 was followed with the added step that groups one and two received Immucox® anticoccidial vaccine orally via gel pads in their pens. The results follow in Tables 5-7, below.

TABLE 5

Group	<i>P. acnes</i>	Vaccine	Challenge	Upper Score	Cecal Score
1	4.0 μ g	Yes	Yes	2.8 ^b	2.1 ^c
2	0.0 μ g	Yes	Yes	2.8 ^b	2.8 ^b
3	0.0 μ g	No	No	0.0 ^c	0.0 ^d

Table 6, below, depicts the number of coccidiosis-related deaths per treatment group six days following the coccidial challenge.

TABLE 6

Group	Treatment	Coccidiosis Deaths
1	4.0 μ g <i>P. acnes</i> , vaccinated, challenged	0
2	0.0 μ g <i>P. acnes</i> , vaccinated, challenged	2
3	0.0 μ g <i>P. acnes</i> , not vaccinated, not challenged	0

Body weights were measured at six days post challenge and the weight gains were calculated. The mean weight gains are illustrated in Table 7, below.

TABLE 7

Group	<i>P. acnes</i> (μ g)	Cocci. Vaccine	Challenge	Gains (gms.)
1	4.0	Yes	Yes	227.8 ^b
2	0.0	Yes	Yes	212.5 ^{b,c}
3	0.0	No	No	278.8 ^a

Discussion and Conclusions

A dose of 4.0 μ g of *P. acnes* given intraperitoneally to day-old broiler chickens enhanced their immune response and decreased the negative effects of coccidiosis when given in combination with an anticoccidial vaccine. Combining *P. acnes* and the anticoccidial vaccine reduced to zero the number of coccidiosis related deaths. Further, there was no mortality from other causes in birds receiving both the *P. acnes* and the anticoccidial vaccine.

Example 4

Example 2, above, was substantially repeated in order to determine an optimum dosage or range thereof of *P. acnes* for intraperitoneal injection. The treatment groups were as follows in Table 8:

TABLE 8

Group	<i>P. acnes</i> dose per chick	Anticoccidial Vaccine	Coccidiosis Challenge	Number of Chicks
1	0	No	No	75
2	0	No	Yes	75
3	0	Yes	No	75
4	0	Yes	Yes	75
5	2.0 μ g	Yes	Yes	75

6	4.0 μg	Yes	Yes	75
7	8.0 μg	Yes	Yes	75
8	16.0 μg	Yes	Yes	75

Discussion and Conclusions

The results of this study indicated that *P. acnes* given intraperitoneally to day-old broiler chickens gave better protection against the effects of coccidiosis than the oral anticoccidial vaccine given alone. Chicks that received 2.0 μg of *P. acnes*, in addition to an oral anticoccidial vaccine, had lower intestinal lesion scores in all areas than those given the vaccine alone. Those that received 4.0 μg of *P. acnes*, in addition to the vaccine, had the lowest lesion scores in all categories than any of the challenged groups.

Further, 4.0 μg of *P. acnes* was significantly better than other levels of *P. acnes*, or vaccine alone, in decreasing the intestinal lesions associated with coccidiosis, and the dose level of 2.0 μg of *P. acnes* gave better weight gains and fewer deaths in addition to lowering the lesion scores. This suggests that a range from about 2.0 to about 4.0 μg is the optimum dose level for intraperitoneal administration to day-old broiler chicks for immune stimulation against the effects of coccidiosis.

Examples 5-15

Examples 1 and 2 are substantially repeated with the modifications in Table 9:

TABLE 9

Example	Mode of Administration of <i>P. acnes</i>	Approx. Age
5	intraperitoneal injection	day zero
6	subcutaneous injection	day zero
7	eye spray	day zero
8	intraperitoneal injection	day three
9	subcutaneous injection	day three
10	eye spray	day three
11	intraperitoneal injection	day seven
12	subcutaneous injection	day seven
13	eye spray	day seven
14	eye spray	three weeks
15	eye spray	four weeks

Discussion and Conclusions

P. acnes stimulates non-specific cell mediated immune response in chicks and effectively decreases the symptoms associated with coccidiosis via intraperitoneal, subcutaneous, or eye spray administration to chicks varying in age from day zero to four weeks old.

Example 16

Domestic broiler (*Gallus domesticus*) embryos (fertile eggs), obtained from a research flock (Peterson males and Arbor Acres females), were placed in Natureform incubators in a poultry research facility. Temperature and humidity were maintained at 99.7°F and 52% humidity. On day 18 of incubation, at transfer from setting to hatching incubators, the eggs were randomly assigned, using a SAS randomization program, to treatment groups as follows:

TABLE 10

Group	<i>P. acnes</i> dose per egg	Immucox	Coccidiosis Challenge	Number of Embryos	Number of Chicks
1	0	No	No	100	60
2	0	No	Yes	100	60
3	0	Yes	No	100	60
4	0	Yes	Yes	100	60
5	4 μ g	Yes	Yes	100	60
6	8 μ g	Yes	Yes	100	60
7	16 μ g	Yes	Yes	100	60

The *P. acnes* was reconstituted and diluted with physiological saline. Those groups selected to receive *P. acnes* treatment were then inoculated using aseptic technique through the large end of the egg at a depth of 1" into the chorioallantoic membrane, with their specific dose of *P. acnes*. The injection volume was 0.1 ml. Groups 2, 3 and 4 did not receive *P. acnes* but were injected in the same manner with physiological saline (sham inoculated). The eggs were then placed, by treatment group, into the baskets of a Natureform hatching incubator and incubated under 99.7°F and 52% humidity until day 21 when all hatched chicks were removed, by group, to continue the study.

At one day of age chicks were moved to an environmentally controlled building. Here they were housed separately by treatment group in 4' x 10' plastic mesh floor pens and placed on fresh litter. Incandescent lamps were used for additional brooding heat.

A standard broiler starter ration and water was available *ad libitum*. Immucox® anticoccidial vaccine available from Vetech Laboratories was administered via the oral route, in Immunogel® gel pad suspension available from Wingo, Inc., to groups 2, 4, 5, 6 and 7 on day one. No other drugs or vaccines were administered during the study.

At approximately 12 days of age, healthy chicks from each treatment group were selected from each treatment group, wing banded with individual numbers, weighed and moved to 6 Petersime battery cages (27" X 27" X 12"), housing 10 birds each. Birds in groups 2, 4, 5, 6 and 7 were challenged with *Eimeria* species as follows: 50,000 *E. tenella*, and 100,000 *E. maxima* (contaminated by approximately 50,000 *E. acervulina*) live oocysts by oral gavage. The excess birds were euthanized and incinerated.

Six days post challenge, all birds were weighed, and euthanized by cervical dislocation. Necropsies were then conducted on all birds and intestinal lesions were scored according to the Johnson and Reid scoring system. All remains were incinerated.

Upper intestinal lesions indicating *E. acervulina* infection, middle intestinal lesions indicating *E. maxima* infection, and cecal lesions indicating *E. tenella* infection, are presented in Table 11, below. General Linear Models (GLM) procedure for ANOVA and Duncan's Multiple Range Test was used for comparisons between treatment groups. Different superscript letters within a column indicate a significant difference ($p \leq 0.05$).

TABLE 11-Intestinal Lesion Scores

Group	<i>P. acnes</i>	Vaccine	Challenge	Ave. Score	Upper Score	Mid Score	Cecal Score
1	0.0 μ g	No	No	0.0 ^d	0.0 ^d	0.0 ^d	0.0 ^d
2	0.0 μ g	No	Yes	2.4 ^a	2.8 ^a	1.5 ^a	3.1 ^a
3	0.0 μ g	Yes	No	0.0 ^d	0.0 ^d	0.0 ^d	0.0 ^d
4	0.0 μ g	Yes	Yes	1.9 ^b	2.2 ^b	1.3 ^{b,c}	2.5 ^b
5	4.0 μ g	Yes	Yes	1.7 ^c	2.0 ^{b,c}	1.1 ^c	2.1 ^{b,c}
6	8.0 μ g	Yes	Yes	1.6 ^c	1.7 ^c	1.2 ^{b,c}	2.0 ^c
7	16.0 μ g	Yes	Yes	1.9 ^b	2.1 ^b	1.3 ^{b,c}	2.4 ^b

The number of coccidiosis deaths six days post coccidial challenge are presented in Table 12, below.

TABLE 12

Group	Treatment	Number of Deaths (%)
1	0.0 μ g <i>P. acnes</i> , no vaccine, no challenge	0 (0)
2	0.0 μ g <i>P. acnes</i> , no vaccine, challenged	6 (10)

3	0.0 μg <i>P. acnes</i> , vaccinated, no challenge	0 (0)
4	0.0 μg <i>P. acnes</i> , vaccinated, challenged	1 (2)
5	4.0 μg <i>P. acnes</i> , vaccinated, challenged	2 (3)
6	8.0 μg <i>P. acnes</i> , vaccinated, challenged	0 (0)
7	16.0 μg <i>P. acnes</i> , vaccinated, challenged	5 (8)

Body weights were measured six days post challenge and the weight gains from day of challenge were calculated. The mean body weight gains are listed in Table 13, below.

TABLE 13

Group	<i>P. acnes</i> Dosage	Immucox Vaccine	Coccidial Challenge	Mean Weight Gains (gms.)
1	0.0	No	No	267.5 ^a
2	0.0	No	Yes	164.0 ^d
3	0.0	Yes	No	218.6 ^b
4	0.0	Yes	Yes	199.0 ^c
5	4.0 μg	Yes	Yes	206.0 ^b
6	8.0 μg	Yes	Yes	160.8 ^d
7	16.0 μg	Yes	Yes	189.0 ^c

Discussion and Conclusions

This study indicated that *P. acnes* is capable of stimulating non-specific cell-mediated immunity against a parasite in chickens when delivered via *in ovo* administration. Dose levels of 4.0 and 8.0 μg of *P. acnes* per embryo at day 18 of incubation followed by an anticoccidial vaccine at one day of age were effective in controlling coccidiosis infections, and were more effective than an anticoccidial vaccine administered alone. Both dose levels of *P. acnes* were better at controlling coccidiosis infections and deaths due to coccidiosis than the higher level of 16.0 μg of *P. acnes*.

Example 17

The procedure from Example 16, above, was substantially repeated in order to determine an optimum dosage or range thereof of *P. acnes* for *in ovo* injection. The treatment groups were as follows in Table 14:

TABLE 14

Group	<i>P. acnes</i> dose per egg	Anticoccidial Vaccine	Coccidiosis Challenge	Number of Embryos	Number of Chicks
1	0	No	No	100	60
2	0	No	Yes	100	60
3	0	Yes	Yes	100	60
4	4.0 μ g	No	Yes	100	60
5	8.0 μ g	No	Yes	100	60
6	4.0 μ g	Yes	Yes	100	60
7	8.0 μ g	Yes	Yes	100	60

The purpose of this study was to determine whether 4.0 or 8.0 μ g of *P. acnes* was the optimal dose, *in ovo*, for the stimulation of immunity as an aid in preventing coccidiosis in broiler chickens. 8.0 μ g of *P. acnes* appeared to be the preferred dose over all parameters. The groups given *P. acnes* with a vaccine did better in all cases than the vaccine alone for all parameters.

Example 18

The procedure from Example 16 is repeated with the exception that *in ovo* inoculation occurs at day 14 of incubation. Non-specific cell-mediated immune response occurs with a resulting decrease in the effects of coccidiosis on the chicks.

Example 19

The procedure from Example 16 is repeated with the exception that *in ovo* inoculation occurs at day 20 of incubation. Non-specific cell-mediated immune response occurs with a resulting decrease in the effects of coccidiosis on the chicks.

The present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative and not restrictive. The present invention is not limited to stimulating an immune response against coccidiosis. To the contrary, the present invention is directed to stimulating non-specific cell mediated immunity against diseases caused by bacteria, viruses, or parasites. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.

What is claimed is:

1. A method for inoculating poultry against disease, comprising the steps of:
 - a) obtaining a solution comprising *Propionibacterium acnes* suspended in a diluent; and
 - b) administering an effective amount of said solution to said poultry via *in ovo* inoculation in order to stimulate a non-specific cell-mediated immune response.
2. A method as recited in Claim 1, further comprising the step of vaccinating said poultry with an anticoccidial vaccine.
3. A method as recited in Claim 2, wherein the anticoccidial vaccine is administered to said poultry simultaneously with the administration of said *Propionibacterium acnes* solution.
4. A method as recited in Claim 2, wherein the anticoccidial vaccine is administered to said poultry following the administration of said *Propionibacterium acnes* solution.
5. A method as recited in Claim 4, wherein the anticoccidial vaccine is administered to said poultry at the age of about day one.
6. A method as recited in Claim 1, wherein said *Propionibacterium acnes* solution is administered to said poultry *in ovo* at least once during a period of time from about day 14 to immediately prior to hatching.
7. A method as recited in Claim 1, wherein said *Propionibacterium acnes* solution is administered to said poultry *in ovo* at least once during a period of time from about day 17 to about day 19.
8. A method as recited in Claim 1, wherein said *Propionibacterium acnes* solution is administered to said poultry *in ovo* at least once during day 18 in development.
9. A method as recited in Claim 1, wherein said diluent comprises a normal saline solution.
10. A method as recited in Claim 1, wherein said diluent comprises an amino acid solution.
11. A method as recited in Claim 1, wherein an effective amount of said solution comprises a dose of *Propionibacterium acnes* in diluent of about $2\mu\text{g}$ /egg to about $12\mu\text{g}$ /egg.
12. A method as recited in Claim 1, wherein an effective amount of said solution comprises a dose of *Propionibacterium acnes* in diluent of about $6\mu\text{g}$ /egg to about $10\mu\text{g}$ /egg.

13. A method as recited in Claim 1, wherein an effective amount of said solution comprises a dose of *Propionibacterium acnes* in diluent of about 8 μg /egg.
14. A method for inoculating poultry against disease, comprising the steps of:
- a) obtaining a solution comprising *Propionibacterium acnes* suspended in a diluent; and
 - b) administering an effective amount of said solution via intraperitoneal injection to said poultry following the hatching thereof in order to stimulate a non-specific cell-mediated immune response.
15. A method as recited in Claim 14, further comprising the step of vaccinating said poultry with an anticoccidial vaccine.
16. A method as recited in Claim 15, wherein the anticoccidial vaccine is administered to said poultry simultaneously with the administration of said *Propionibacterium acnes* solution.
17. A method as recited in Claim 15, wherein the anticoccidial vaccine is administered to said poultry following the administration of said *Propionibacterium acnes* solution.
18. A method as recited in Claim 17, wherein the anticoccidial vaccine is administered to said poultry at the age of about day three.
19. A method as recited in Claim 14, wherein said *Propionibacterium acnes* solution is administered to said poultry at least once during a period of time immediately following the hatching of said poultry to the age of about day seven.
20. A method as recited in Claim 14, wherein said *Propionibacterium acnes* solution is administered to said poultry at least once during a period of time when said poultry is younger than about three days old.
21. A method as recited in Claim 14, wherein said *Propionibacterium acnes* solution is administered to said poultry at least once during a period of time when said poultry is about one day old.
22. A method as recited in Claim 14, wherein said diluent comprises a normal saline solution.
23. A method as recited in Claim 14, wherein said diluent comprises an amino acid solution.
24. A method as recited in Claim 14, wherein an effective amount of said solution comprises a dose of *Propionibacterium acnes* in diluent of about 0.5 μg /chick to about 16 μg /chick.

25. A method as recited in Claim 14, wherein an effective amount of said solution comprises a dose of *Propionibacterium acnes* in diluent of about 1.5 μg /chick to about 3.5 μg /chick.
26. A method as recited in Claim 14, wherein an effective amount of said solution comprises a dose of *Propionibacterium acnes* in diluent of about 2 μg /chick.
27. A method for inoculating poultry against disease, comprising the steps of:
- a) obtaining a solution comprising *Propionibacterium acnes* suspended in a diluent; and
 - b) administering an effective amount of said solution via subcutaneous injection to said poultry following the hatching thereof in order to stimulate a non-specific cell-mediated immune response.
28. A method as recited in Claim 27, further comprising the step of vaccinating said poultry with an anticoccidial vaccine.
29. A method as recited in Claim 28, wherein the anticoccidial vaccine is administered to said poultry simultaneously with the administration of said *Propionibacterium acnes* solution.
30. A method as recited in Claim 28, wherein the anticoccidial vaccine is administered to said poultry following the administration of said *Propionibacterium acnes* solution.
31. A method as recited in Claim 30, wherein the anticoccidial vaccine is administered to said poultry at the age of about day three.
32. A method as recited in Claim 27, wherein said *Propionibacterium acnes* solution is administered to said poultry at least once during a period of time immediately following the hatching of said poultry to the age of about day seven.
33. A method as recited in Claim 27, wherein said *Propionibacterium acnes* solution is administered to said poultry at least once during a period of time when said poultry is younger than about three days old.
34. A method as recited in Claim 27, wherein said *Propionibacterium acnes* solution is administered to said poultry at least once during a period of time when said poultry is about one day old.
35. A method as recited in Claim 27, wherein said diluent comprises a normal saline solution.
36. A method as recited in Claim 27, wherein said diluent comprises an amino acid solution.

37. A method as recited in Claim 27, wherein an effective amount of said solution comprises a dose of *Propionibacterium acnes* in diluent of about 0.5 μg /chick to about 16 μg /chick.
38. A method as recited in Claim 27, wherein an effective amount of said solution comprises a dose of *Propionibacterium acnes* in diluent of about 1.5 μg /chick to about 3.5 μg /chick.
39. A method as recited in Claim 27, wherein an effective amount of said solution comprises a dose of *Propionibacterium acnes* in diluent of about 2 μg /chick.
40. A method for inoculating poultry against disease, comprising the steps of:
- a) obtaining a solution comprising *Propionibacterium acnes* suspended in a diluent; and
 - b) administering an effective amount of said solution via an eye spray to said poultry following the hatching thereof in order to stimulate a non-specific cell- mediated immune response.
41. A method as recited in Claim 40, further comprising the step of vaccinating said poultry with an anticoccidial vaccine.
42. A method as recited in Claim 41, wherein the anticoccidial vaccine is administered to said poultry at approximately the same time as the administration of said *Propionibacterium acnes* solution.
43. A method as recited in Claim 41, wherein the anticoccidial vaccine is administered to said poultry following the administration of said *Propionibacterium acnes* solution.
44. A method as recited in Claim 43, wherein the anticoccidial vaccine is administered to said poultry at the age of about three weeks.
45. A method as recited in Claim 40, wherein said *Propionibacterium acnes* solution is administered to said poultry at least once during a period of time immediately following the hatching of said poultry to the age of about four weeks.
46. A method as recited in Claim 40, wherein said *Propionibacterium acnes* solution is administered to said poultry at least once during a period of time when said poultry is younger than about three weeks old.
47. A method as recited in Claim 40, wherein said *Propionibacterium acnes* solution is administered to said poultry at least once during a period of time when said poultry is about one day old.
48. A method as recited in Claim 40, wherein said diluent comprises a normal saline solution.

49. A method as recited in Claim 40, wherein said diluent comprises an amino acid solution.
50. A method as recited in Claim 40, wherein an effective amount of said solution comprises a dose of *Propionibacterium acnes* in diluent of about 2 μg /chick to about 16 μg /chick.
51. A method as recited in Claim 40, wherein an effective amount of said solution comprises a dose of *Propionibacterium acnes* in diluent of about 6 μg /chick to about 10 μg /chick.
52. A method as recited in Claim 1, wherein an effective amount of said solution comprises a dose of *Propionibacterium acnes* in diluent of about 8 μg /chick.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/03498

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/184.1, 245.1, 246.1, 422, 193.1, 204.1, 265.1, 267.1, 816, 826; 435/525.1, 252.32

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,372,810 A (ONISHI et al) 13 December 1994, see entire document.	14-52
Y	COATES et al. The inhibitory effect of Corynebacterium parvum and Pasteurella multocida pretreatment of Staphylococcal synovitis in turkeys. Avian Diseases. 1977, Vol. 21, No. 2, pages 319-322, see entire document.	1-52
A	DREWS, J. Immunostimulation: Clinical and Experimental Perspectives. Klin. Wochenschr. 1984, Vol. 62, pages 254-264, see especially 255-256.	1-52



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

01 APRIL 1999

Date of mailing of the international search report

25 MAY 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Telephone No. (703) 305-3230

Authorized officer

NITA M. MINNIFIELD

Telephone No. (703) 308-0196

JOYCE BRIDGERS
PARALEGAL SPECIALIST
CHEMICAL MATRIX

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/03498

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	CORRIER et al. Effects of Corynebacterium parvum on the resistance of young chickens to Salmonella typhimurium infection. Poultry Science. 1989, Vol. 68, Suppl. 1, page 34. see abstract 2.	1-52
A	SMITH, R. Embrex receives approval for first in ovo IBD vaccine. Feedstuffs. 17 March 1997.	1-52
Y	VANSELOW, B. A. The application of adjuvants to veterinary medicine. Veterinary Bulletin. November 1987, Vol. 57, No. 11, pages 881-896, especially pages 881-882, 886-887	1-52
Y	LILLEHOJ, et al. Adjuvnticity of dimethyl dioctadecyl ammonium bromide, complete freund's adjuvant and Corynebacterium parvum with respect to host immune response to coccidial antigens. Avian Diseases. 1993, Vol. 37, pages 731-740, see entire document.	1-52
Y	An automated In-Ovo vaccine delivery system providing improved bird performance and reduced hatchery operating costs. In: EMBREX INC. "Anonymous" INOVOJECT Brochure, 1992.	1-13
Y	US 5,540,924 A (ONISHI et al) 30 July 1996, see entire document.	14-52
A	DONAHOE et al. Resistance to Marek's disease. Effect of Corynebacterium parvum and Marek's tumor cell vaccines on tumorigenesis in chickens. J. Natl. Cancer Inst. April 1978, Vol. 60, No. 4, pages 829-833, see entire document.	1-52
A	MCDUGALD, L. R. Coccidiosis prevention, treatment. Poultry Digest. March 1994, Vol. 53, No. 3, pages 20-21, see entire document.	1-52
A	US 4,663,306 A (CANTRELL) 05 May 1987, see entire document.	1-52

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/03498

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6): A61K 39/00, 39/38, 39/385, 39/12, 39/05, 39/07, 39/002, 39/012; C12N 1/12, 1/20

A. CLASSIFICATION OF SUBJECT MATTER:

US CL : 424/184.1, 245.1, 246.1, 422, 193.1, 204.1, 265.1, 267.1, 816, 826; 435/525.1, 252.32

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, EMBASE, MEDLINE, BIOSIS, CABA, AGRICOLA, JAPIO, WPIDS, BIOTECHDS, LIFESCI, CONFSCI, CAPLUS

search terms: inventor names, poultry, chicken avian, P.acnes, immunostimulant, cell mediated immunity, immun?, corynebacterium, coccidiosis, in ovo, hatchling, administration, adjuvant, immunoadjuvant, disease, infection, eimeria, anticoccidial, vaccine